Archive

Roivant’s $14M bet on Bayer’s inhaled hypertension med pays off with phase 2 win

An inhaled pulmonary hypertension therapy showing phase 2 benefit could offer a more targeted option for patients who struggle with systemic side effects from oral vasodilators.

Medicine · Fierce Biotech · 6d

The changing therapeutic landscape of small-cell lung cancer.

No quantitative results reported; describes emerging targeted therapies including T-cell engagers, antibody-drug conjugates, radioconjugates, and cell therapies showing early promise.

Oncology · Lancet · 6d

Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial.

Overall survival hazard ratio 1.04 (95% CI 0.69-1.58; p=0.58). 2-year OS 82% in both groups. Grade 3+ adverse events 12% vs 3%.

Oncology · Lancet · 6d

Delhi HC backs NMC: Fragmented foreign medical degrees not enough for FMGE eligibility

If you supervise or train FMGE aspirants, this ruling tightens verification—fragmented foreign training won't qualify, affecting recruitment and credential checks.

General Medicine · ETHealthworld · 7d

Liposuction versus conservative therapy for patients with lipoedema in Germany: a multicentre, randomised controlled clinical trial.

68% (190/278) achieved ≥2-point pain reduction with liposuction vs 8% (10/132) with conservative therapy (OR 26.2, 95% CI 13.1-52.5). Serious adverse events: 8% vs 3%.

General Surgery · Lancet · 7d

Novartis Lp(a) drug fails to lower cardiovascular risk in closely watched ph. 3 trial

Despite lowering Lp(a), this drug did not cut heart attack or stroke risk—so don't start checking Lp(a) routinely yet.

Cardiology · Fierce Biotech · 8d

FDA Takes Steps to Maintain Newborn Access to Life-Saving Starter Nutrition Products

Ensures neonatal intensive care units can keep stocking starter PN for premature infants during potential shortages, preventing treatment delays.

Paediatrics · FDA — Press Announcements · 8d

FDA Grants Accelerated Approval to a New Breast Cancer Treatment

For oncologists in India, this approval signals a new option for advanced breast cancer, but check local availability and cost before changing practice.

Oncology · FDA — Press Announcements · 8d

Ionis’ ‘breakthrough’ Alexander disease approval establishes pillar of rare disease pipeline

First therapy for Alexander disease—an ASO targeting GFAP—offers a disease-modifying option for a fatal leukodystrophy, though availability in India remains unclear.

Neurology · Fierce Biotech · 8d

Menarini signs $771M deal to take Gan & Lee GLP-1 to European market

A new GLP-1 for obesity and diabetes is entering Europe; watch for pricing and supply competition that may affect your patients' access.

Endocrinology · Fierce Biotech · 8d

Medulance Raises ₹24 Cr To Expand Emergency Response Network

Expands ambulance availability and response times for your patients in emergencies, potentially improving critical care access across cities.

General Medicine · Inc42 · 8d

Smoking raises death risk by 55% in people with diabetes, global experts call for active quit treatment

For your diabetic patients who smoke, actively offer cessation—this consensus quantifies a 55% higher death risk and urges routine intervention.

Endocrinology · ETHealthworld · 8d

FSSAI plans curbs on high-fat food sales within 50 metres of schools, CEO Rajit Punhani says

This may reduce childhood obesity and metabolic risk; paediatricians should counsel families on healthier snack choices near schools.

Paediatrics · ETHealthworld · 8d

FDA Approves First Drug to Treat Alexander Disease

First-ever therapy for a fatal leukodystrophy; consider referral for pediatric or adult patients with confirmed GFAP mutation.

Neurology · FDA — Press Announcements · 9d

Ultrahuman Bags $70 Mn To Build An Integrated Healthtech Platform

This funding expands wearable health monitoring, potentially aiding early detection of metabolic and cardiac issues in your patients.

Medicine · Inc42 · 9d

GenHealth.ai secures $16.5M in series A for back-office AI agents

If adopted, these agents could reduce manual revenue-cycle work across EHRs and payer portals, freeing staff time and potentially improving claim throughput.

Medicine · Fierce Healthcare · 9d

STAT+: OpenEvidence launches new family of AI models

If these models improve clinical evidence retrieval, you may get faster, more accurate answers at the point of care—worth trialing in your workflow.

General Medicine · STAT News — Health Tech · 9d

Psilocybin proves promising in neuropathic pain mouse study

If confirmed in humans, psilocybin could offer a new option for chemotherapy-induced neuropathy, which often resists standard painkillers.

Neurology · Fierce Biotech · 9d

AbbVie’s bispecific T-cell engager shows promise in ph. 3 multiple myeloma trial

For relapsed/refractory myeloma patients who have exhausted standard options, etentamig offers a new bispecific with improved PFS—consider as a later-line therapy.

Oncology · Fierce Biotech · 9d

STAT+: FDA pilot offers generative AI medical devices a path to patients before they are authorized

FDA's TEMPO pilot may let AI tools like Cadence and Limbic reach your patients pre-authorization—know their evidence limits before you rely on them.

Medicine · STAT News — Health Tech · 9d

OpenEvidence deepens oncology push to enhance specialized AI agent, launches new AI model family

Specialised AI agents may give faster, more accurate oncology answers at the point of care, potentially aiding treatment decisions.

Oncology · Fierce Healthcare · 9d

Scientists find genes linked to OCD, raising the prospect of new treatments

Identifies specific genetic loci for OCD, guiding future targeted therapies and better risk stratification for your patients with refractory symptoms.

Psychiatry · ETHealthworld · 9d

Porcine kidney xenotransplantation as a bridge to allotransplantation: a first-in-human study.

Xenograft sustained dialysis independence for 271 days. Early T-cell rejection resolved. Later graft failure from thrombotic microangiopathy despite negative crossmatch. No porcine pathogen transmission. Anti-HLA antibodies unchanged. Human transplant succeeded with 231 days follow-up.

General Surgery · Lancet · 9d

Natural history and clinical impact of epilepsy in adults with Down syndrome: a multicentre clinical study.

Cumulative incidence of epilepsy increased from 9.5% (95% CI 7.8-11.3) at Alzheimer's diagnosis to 56.9% (51.7-61.7) after 9 years. Epilepsy associated with increased mortality (HR 2.10 [95% CI 1.57-2.82]; p<0.0001) and faster cognitive decline.

Neurology · Lancet · 9d

GSK pens $1.3B Hutchmed deal for early-stage KRAS-EGFR cancer asset

This deal may bring a novel KRAS-EGFR targeted therapy to your patients with solid tumors, potentially expanding options beyond current KRAS inhibitors.

Oncology · Fierce Biotech · 9d

Pulmonary Nodules.

Solid nodules stable for 2 years considered benign; subsolid nodules require longer stability. Subsolid nodules slower growing but higher malignancy risk, especially if solid component develops.

Radiology · NEJM · 10d

Beyond cold to hot: oncolytic virotherapy as the next cornerstone of immuno-oncology.

Argues first-generation viruses and checkpoint inhibitors rely on pre-existing tumour-specific T cells. Next-generation viruses act as antigen-agnostic in situ vaccines, with early data showing T-cell broadening, abscopal responses, and survival benefit in ICI-refractory disease.

Medicine · Nature reviews. Clinical oncology · 10d

Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.

Median event-free survival 14.5 months (95% CI 10.4-24.4) with azacitidine-venetoclax vs 6.2 months (95% CI 4.1-10.1) with induction; HR 0.57 (95% CI 0.39-0.84, P=0.002).

Oncology · NEJM · 10d

Genetic evidence supports the combined targeting of lipoprotein(a) and LDL cholesterol to reduce coronary artery disease risk.

LPA or PCSK9 loss-of-function carriers had lower CAD risk than noncarriers (odds ratio 0.91 and 0.81); carriers of both had lower risk still (OR 0.73). Genetic lowering of Lp(a) and LDL-C gave OR 0.70 versus OR 0.85 and 0.81 individually.

Medicine · Nature cardiovascular research · 10d

Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer.

Objective response: 31% at ≤120 mg, 34% at 160-220 mg, 37% at 300 mg. Grade 3+ adverse events in 54%; pneumonia 10%, diarrhea 9%, rash 8%, anemia 5%; four grade 5 events.

Oncology · NEJM · 10d

BCL-2 inhibition at antiretroviral therapy initiation reduces the intact SIV reservoir in macaques.

A rapid and sustained reduction of the intact SIV reservoir was seen in venetoclax-treated rhesus macaques in blood and lymph nodes.

Medicine · Nature microbiology · 10d

ANA: Individuals, employers share responsibility in tackling nurse fatigue

For clinicians, this shifts fatigue from personal failing to systemic duty—prompting safer staffing and rest policies that protect you and your patients.

Medicine · Fierce Healthcare · 10d

Vitamin D3 more effective than Vitamin D2 in maintaining muscle, heart health: ICMR-NIN study

Prefer D3 supplements for patients needing vitamin D, as D2 may inadequately protect muscle and cardiac structure.

Endocrinology · ETHealthworld · 10d

Leading medical groups release flu, COVID vaccine recommendations as CDC guidance lags

With CDC silent, these recommendations give you a clear vaccination schedule for flu and COVID to follow this season.

General Medicine · Fierce Healthcare · 10d

Teva autoimmune antibody notches ph. 2 win in celiac disease

For celiac patients who still flare on a gluten-free diet, this IL-15 blocker may offer the first targeted option—watch for phase 3.

Gastroenterology · Fierce Biotech · 10d

COVID-19 Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season.

Vaccine effectiveness against hospitalization: 53.0% (95% CI, 37.0%-65.0%) in ≥65 years (2025-26) and 54.0% (95% CI, 1.0%-78.0%) in 18-64 years (2024-25). Maternal vaccination reduced infant hospital contacts by 50.0%-54.0%.

General Medicine · JAMA · 11d

Is Moderna, Merck's mRNA cancer vaccine win the start of a 'personalized medicine revolution'?

A phase 3 mRNA vaccine plus pembrolizumab improved survival in resected high-risk melanoma; expect referral pathways and adjuvant trial discussions to shift if approved.

Oncology · Fierce Biotech · 11d

ChatGPT for Healthcare unveils new integrations with Epic, public health data sources

If you use Epic, ChatGPT may soon sit inside your workflow, pulling patient data and public health context—potentially saving clicks but demanding vigilance on accuracy.

General Medicine · Fierce Healthcare · 11d

Cureety acquires Reimagine Care for AI-driven precision oncology

This merger expands AI-driven remote monitoring and care pathways to over 250 cancer centers, potentially improving symptom management and outcomes for your patients.

Oncology · Fierce Healthcare · 11d